Edinburgh Research Explorer

The structural basis of Mos1 transposase inhibition by the anti-retroviral drug Raltegravir

Research output: Contribution to journalArticle

Related Edinburgh Organisations

Open Access permissions

Open

Documents

Original languageEnglish
Pages (from-to)743–751
JournalAcs chemical biology
Volume9
Issue number3
DOIs
Publication statusPublished - 7 Jan 2014

Abstract

DNA transposases catalyse the movement of transposons around genomes by a cut-and-paste mechanism related to retroviral integration. Transposases and retroviral integrases share a common RNaseH-like domain with a catalytic DDE/D triad that coordinates the divalent cations required for DNA cleavage and integration. The anti-retroviral drugs Raltegravir and Elvitegravir inhibit integrases by displacing viral DNA ends from the catalytic metal ions. We demonstrate that Raltegravir, but not Elvitegravir, binds to Mos1 transposase in the presence of Mg2+ or Mn2+, without the requirement for transposon DNA, and inhibits transposon cleavage and DNA integration in biochemical assays. Crystal structures at 1.7 Å resolution show Raltegravir, in common with integrases, coordinating two Mg2+ or Mn2+ ions in the Mos1 active site. However, in the absence of transposon ends, the drug adopts an unusual, compact binding mode distinct from that observed in the active site of the prototype foamy virus integrase.

Download statistics

No data available

ID: 12418271